Amerikanische Gesellschaft für Hirudotherapie

How serious a problem is bleeding in patients with acute coronary syndromes?

Review published in Current cardiology reports (2011)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungSicherheit & InfektionskontrolleSpeichel-PharmakologieBaber U et al. · Current cardiology reports, 2011

Abstract

Recent studies have highlighted the critical importance of bleeding complications on prognosis in patients with acute coronary syndromes (ACS). In fact, the hazard for an adverse cardiovascular event associated with bleeding is similar to that of a myocardial infarction. Several bleeding risk scores are now available that reliably quantify the probability of an ACS patient experiencing a bleeding complication. Consistent and strong correlates of bleeding include older age, female sex, renal impairment, and an invasive management approach. Although patients who tend to bleed are usually more morbid compared with their non-bleeding counterparts, several lines of experimental and clinical evidence suggest an independent and causal pathway for bleeding-associated cardiovascular risk. Given the frequency and adverse prognosis associated with bleeding, interventions that might reduce such complications are now a major emphasis in the current era of ACS treatment. Recent trials have shown that several novel antithrombotics, bivalirudin and fondaparinux, reduce bleeding risk while maintaining efficacy in reducing ischemic events during ACS. Other promising strategies that continue to be tested include the use of vascular closure devices and transradial arterial access during percutaneous coronary intervention.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAcute Coronary SyndromeAnticoagulantsFibrinolytic AgentsFondaparinuxHemorrhageHirudinsHumansIncidencePeptide FragmentsPlatelet Aggregation InhibitorsPolysaccharidesPrognosis

Zusammenfassung

Recent studies have highlighted the critical importance of bleeding complications on prognosis in patients with acute coronary syndromes (ACS).

Warum dies für die Hirudotherapie relevant ist

This review article examines the prognostic significance of bleeding complications in patients with acute coronary syndromes (ACS) and discusses interventions that may reduce such risks. The abstract highlights that bleeding correlates with older age, female sex, renal impairment, and invasive management, and reports that recent trials have shown the novel antithrombotics bivalirudin and fondaparinux reduce bleeding risk while maintaining efficacy in reducing ischemic events during ACS treatment. The abstract does not mention leeches, hirudotherapy, hirudin, or the leech secretome, and provides no information about the origin or derivation of bivalirudin. Therefore, this article has no apparent relevance to the American Society of Hirudotherapy based on its abstract alone.

Zitation

How serious a problem is bleeding in patients with acute coronary syndromes?

Baber U et al. · Current cardiology reports, 2011

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.